Novo Nordisk A/S

New York Stock Exchange
Back to all articles
Somewhat Bearish -40

Novo Nordisk (NVO) Stock Drops After Morgan Stanley Downgrade on Patent Cliff Concerns

AI-generated analysis

📉 Morgan Stanley downgraded Novo Nordisk (NVO) from Equal-weight to Underweight while maintaining a price target of 250 Danish crowns.

📊 NVO shares fell approximately 2.4% in Copenhagen trading immediately following the analyst downgrade announcement.

💊 Semaglutide, used in Ozempic and Wegovy, represents 75% of Novo Nordisk's revenue but faces significant patent expiration risks in the early-to-mid 2030s.

📉 Analysts project only a 4% compound annual growth rate for NVO's revenue and EBIT between 2027 and 2030, lagging behind European pharmaceutical sector expectations.

⚠️ Morgan Stanley warns that the company's oral obesity pipeline, projected to hit $10 billion in sales by 2031, will not be enough to offset pricing headwinds and generic competition.

🏥 A proprietary survey suggests NVO faces market share erosion over the next 18 months due to Eli Lilly's portfolio and its upcoming retatrutide candidate launching in 2027.

💰 Novo Nordisk trades at a 35% premium versus global competitors like Sanofi and GSK that face comparable patent expiration challenges, despite trading at a discount to European peers.

🗓️ The company is scheduled for a capital markets presentation on September 21, where management is expected to discuss its oral obesity strategy and business development initiatives.

Bullish Signals
  • Novo Nordisk's oral obesity product pipeline is projected to achieve $10 billion in annual sales by 2031.
  • Semaglutide is expected to still represent 59% of total sales in 2031, even as patent exclusivity begins to expire.
Risk Factors
  • Morgan Stanley downgraded the stock to Underweight due to concerns that the current valuation fails to account for a lackluster medium-term expansion trajectory.
  • The company faces significant revenue risks from semaglutide patent expirations in Europe and the United States during the early-to-mid 2030s.
  • The company faces anticipated market share erosion over the next 18 months driven by Eli Lilly's existing portfolio and its forthcoming retatrutide candidate.
  • Novo Nordisk trades at a 35% premium versus global competitors confronting comparable patent expiration challenges, including Sanofi and GSK.
Full Analysis
Morgan Stanley downgraded Novo Nordisk (NVO) from Equal-weight to Underweight, citing concerns over a looming patent cliff for its blockbuster drug semaglutide. The analyst team maintained a price target of 250 Danish crowns but warned that the current valuation does not adequately reflect a lackluster medium-term growth trajectory. Following the announcement, NVO shares declined approximately 2.4% during early trading in Copenhagen. The core of Morgan Stanley's bearish thesis centers on semaglutide, which accounts for 75% of Novo Nordisk's revenue and faces patent expirations in Europe and the United States between the early-to-mid 2030s. While the drug is expected to still represent 59% of total sales in 2031, analysts project only a 4% compound annual growth rate for both revenue and EBIT from 2027 to 2030. This forecast trails the broader European pharmaceutical sector, which Morgan Stanley expects to grow at 4% for revenue and 7% for EBIT during the same period. Despite acknowledging that Novo Nordisk's oral obesity pipeline could reach $10 billion in annual sales by 2031, analysts caution this will not offset pricing pressures and competitive headwinds. A proprietary survey of primary care practitioners indicates anticipated market share erosion over the next 18 months due to competition from Eli Lilly's existing portfolio and its upcoming retatrutide candidate. Consequently, NVO trades at a 35% premium versus global competitors facing similar patent expiration challenges, such as Sanofi and GSK.